For de som husker R&D dagen i fjor, det snakket JD mye om Damage Response Inhibitors. Pussig nok fremheves dette også i dealen mellom AZ og Fusion!
The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DNA Damage Response Inhibitors (DDRis).